Since accumulating studies have confirmed that TGF-β/Smad3 signaling plays extensive regulatory roles in the development and progression of multiple types of cancers, we next conducted Western blot assays to assess the effects of SCRN1 knockdown on the activity of TGF-β/Smad3 signaling. The gene discussed is SMAD3; the disease is cancer.